Centocor (www.centocor.com) extended its license agreement with Medarex (www.medarex.com) related to antibody development. The company thus will have continued access to Medarex’ UltiMAb Human Antibody Development System® to be used against an unlimited number of targets. Centocor says that it first licensed the UltiMAb technology in 1997 and expanded the agreement in 2000.
